Combined Adult Neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model

January 30, 2024

Doo Yeon Kim, Rudolph Tanzi, Se Hoon Choi

New tricks for an ancient system: physiological and pathological roles of complement in the CNS

January 30, 2024

Beth Stevens

A Comparison of Popular TDT-generalizations for family-based association analysis

January 30, 2024

Christoph Lange

Studying Synaptically Evoked Cortical Responses ex vivo With Combination of a Single Neuron Recording (Whole-Cell) and Population Voltage Imaging (Genetically Encoded Voltage Indicator)

January 30, 2024

Srdjan D. Antic

Plasminogen mediates communication between the peripheral and central immune system during systemic immune challenge with lipopolysaccharide

January 30, 2024

Erin H. Norris, Sidney Strickland

Seed-competent tau monomer initiates pathology in a tauopathy mouse model

January 30, 2024

Marc Diamond

Diabetes-associated SorCS1 regulates Alzheimer’s amyloid-beta metabolism: evidence for involvement of SorL1 and the Retromer Complex

January 30, 2024

Rudolph Tanzi, Sam Gandy

THE EFFECT OF THE MENOPAUSAL TRANSITION PERIOD ON THE BRAIN

Throughout a single lifetime, the brain undergoes many changes. In early development, brain circuits are connected and pruned; in adolescence circuits mature and, in midlife, the menopause transition (MT) impacts a host of brain functions—from energy metabolism to synaptogenesis. Despite the clear link between MT and brain function, very little ...

December 7, 2021

ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components

January 30, 2024

Guojun Bu, Takahisa Kanekiyo

New Drug for Alzheimer’s Disease – ADUHELM – Update January 31, 2024

***** On January 31, 2024, in a press release, Biogen announced that it is discontinuing production of Aduhelm. From the release, “The company will discontinue the development and commercialization of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study.”  *****  On April 7, 2022, the ...

May 3, 2022